Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Mesoblast Limited
Mesoblast Limited News
Mesoblast Limited Quantitative Score
About Mesoblast Limited
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
Mesoblast Limited Earnings & Revenue
Mesoblast Limited Financials
Table Compare
Compare MESO metrics with: | |||
|---|---|---|---|
Earnings & Growth | MESO | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | MESO | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | MESO | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | MESO | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Mesoblast Limited Income
Mesoblast Limited Balance Sheet
Mesoblast Limited Cash Flow
Mesoblast Limited Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Mesoblast Limited Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
Mesoblast Limited Executives
| Name | Role |
|---|---|
| Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons) | Founder, Chief Executive Officer, MD, Chairman of Scientific Advisory Board & Executive Director |
| Dr. Eric A. Rose M.D. | Chief Medical Officer & Executive Director |
| Dr. Paul J. Simmons BSc, Ph.D. | Scientific Advisor to the Chief Executive Officer |
| Mr. Andrew Chaponnel B.Com. | Interim Chief Finance Officer |
| Mr. Justin Horst B.S. | Head of Manufacturing |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons) | Founder, Chief Executive Officer, MD, Chairman of Scientific Advisory Board & Executive Director | 1957 | 1.21M | |
| Dr. Eric A. Rose M.D. | Chief Medical Officer & Executive Director | 1951 | 1.01M | |
| Dr. Paul J. Simmons BSc, Ph.D. | Scientific Advisor to the Chief Executive Officer | 1959 | -- | |
| Mr. Andrew Chaponnel B.Com. | Interim Chief Finance Officer | Male | -- | |
| Mr. Justin Horst B.S. | Head of Manufacturing | Male | -- |